When you’re living with a rare condition like hereditary ATTR (hATTR) amyloidosis, the last thing you need is confusion about your treatment options. Two medications — patisiran (Onpattro) and vutrisiran (Amvuttra) — may seem similar, but understanding their differences can help you make informed treatment choices.

Both medications treat hATTR amyloidosis and work in similar ways by reducing production of transthyretin (TTR) protein. However, they differ in several ways — including how they’re given, how often they’re needed, and their potential side effects.

Ways Onpattro and Amvuttra Are Alike

Onpattro and Amvuttra are medications used to treat nerve symptoms caused by hATTR amyloidosis. This is a rare, inherited condition in which a protein called transthyretin builds up in the nerves, heart, and other organs.

🗳️ Have you used patisiran (Onpattro) or vutrisiran (Amvuttra) to treat your hATTR amyloidosis?

Yes, I’ve used Onpattro.

Yes, I’ve used Amvuttra.

Yes, I’ve used both Onpattro and Amvuttra.

No, I haven’t used either.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

Over time, amyloid deposits can damage tissues, including nerves — leading to symptoms like tingling, weakness, or nerve pain in the hands and feet (neuropathy). When many nerves are affected, it’s known as polyneuropathy.

Both drugs belong to a class of treatments known as RNA interference (RNAi) therapies. These treatments work by reducing the production of TTR proteins before they can build up and cause harm.

Onpattro and Amvuttra are also considered disease-modifying therapies, not just treatments for symptoms. That means they’re designed to help slow disease progression. In studies, many people taking either drug experienced slower worsening of nerve problems and, in some cases, significant improvements in daily activities.

They haven’t been tested in head-to-head clinical trials, but no major differences in effectiveness have been noted between the two medications. Both agents help reduce nerve damage and support quality of life for people living with hATTR amyloidosis.

Next, let’s look at the key differences.

One of the biggest practical differences between these two treatments is how often they’re administered.

That means Amvuttra requires only four doses per year, compared to 17 or more doses for Onpattro. For people who have mobility challenges, busy work schedules, or long travel times to infusion centers, Amvuttra may be easier to fit into daily life.

That said, some people may appreciate the regular in-person check-ins that come with Onpattro infusions. Choosing between the two often comes down to your lifestyle, preferences, and what feels manageable for you.

Another key difference is how each medication is given.

Onpattro infusions take longer, may require time off work, and require premedications (medicines given beforehand) to help prevent infusion reactions. In contrast, Amvuttra’s injection may be quicker and more convenient — especially for people who prefer to avoid IVs.

Onpattro can cause infusion-related reactions, including fever, shortness of breath, swelling, and dizziness.

To help prevent these reactions, people are given premedications at least 60 minutes before each Onpattro infusion. These include a corticosteroid, acetaminophen, and antihistamines, which can have their own side effects.

Amvuttra is given under the skin rather than by infusion and does not require these premedications. It was generally well tolerated in studies. Some people may experience mild skin discoloration, swelling, or tenderness at the injection site.

For people who’ve had difficulty with infusion reactions in the past, Amvuttra may be a more comfortable option.

Onpattro was the first RNAi therapy, approved by the U.S. Food and Drug Administration (FDA) in 2018. It has a longer track record in clinical practice, with long-term safety data from follow-up studies.

Amvuttra, approved in 2022, is newer. It uses the same core approach to treatment — targeting and reducing production of TTR protein — but with differences like less frequent dosing.

A 2026 analysis of HELIOS-B found fewer digestive problems with Amvuttra than with a placebo (an inactive treatment) in people with ATTR-related cardiomyopathy (heart muscle disease). A longer-term Amvuttra follow-up study (HELIOS-A) in people with polyneuropathy demonstrated sustained benefits.

Some people may prefer a more established treatment, but a longer history of use does not necessarily mean a drug is safer or better for you.

There’s no official guideline saying which drug should be used first. Doctors often make personalized recommendations based on each person’s needs and preferences.

For example, someone who travels frequently or lives far from an infusion center may prefer Amvuttra’s less frequent dosing schedule. On the other hand, a person who’s already doing well on Onpattro may choose to stay on it rather than switch to the newer medication.

Doctors also may consider:

Some specialists may lean toward Amvuttra for newly diagnosed individuals because of its convenience and lack of required premedications, but most decisions are made case by case, in partnership with the person receiving treatment.

Both Onpattro and Amvuttra are FDA-approved to treat polyneuropathy caused by hATTR amyloidosis in adults. Amvuttra is also approved to treat cardiomyopathy due to wild-type or hereditary ATTR amyloidosis in adults. Neither medication is currently approved for anyone younger than 18.

If you care for a child, teen, or young adult with a family history of hATTR amyloidosis, talk with your doctor or a genetic counselor about when to consider genetic testing. For children without symptoms, testing is generally deferred until adulthood. Your care team can explain which early signs to watch for and when monitoring may be helpful.

The cost of both medications can be high, but what you actually pay out of pocket depends on your insurance plan. Factors that can affect coverage include:

Amvuttra is given less frequently and doesn’t require premedications or an IV infusion, which may reduce travel and appointment time. However, fewer visits do not necessarily mean lower out-of-pocket costs, and insurance coverage varies.

To understand what’s financially practical for you, talk with your healthcare provider and any available financial support programs. They can help you navigate your insurance benefits and find the most affordable treatment path.

Ask Questions and Stay Informed

Onpattro and Amvuttra are both important advances in the treatment of hATTR amyloidosis. These therapies reduce TTR protein production to help slow the disease — not just manage its symptoms.

Ask your care team about side effects, monitoring needs, insurance coverage, and what to expect over time. Consider connecting with others who are navigating hATTR amyloidosis — many people are eager to share what they’ve learned.

Onpattro Side Effects

Some people experience infusion-related side effects from Onpattro. Some of these reactions may be life-threatening and require immediate medical attention. Tell your care team immediately if you experience:

The medication itself may also cause other side effects, most commonly upper respiratory infections. Other potential Onpattro side effects may include back pain, headache, difficulty breathing, or cold or flu symptoms.

Onpattro can also lower vitamin A levels and may affect your vision. Amvuttra also lowers vitamin A, and people taking either drug should take the recommended daily allowance of vitamin A as directed by their healthcare provider. Contact your doctor about vision changes or other unusual symptoms.